Dec '25 • General discussion
Periprosthetic Joint Infection 2025: Novel Treatments & Diagnostic Advances with Videos
🦠 **2025 ADVANCES: Periprosthetic Joint Infection**
Latest diagnostic breakthroughs, treatment innovations, and surgical video demonstrations
📊 **KEY 2025 PJI ADVANCES:**[web:223]
**Clinical Challenge:**
• Most severe complication after joint arthroplasty
• Significant patient morbidity
• High healthcare costs
• High failure rates with conventional treatments
• Growing burden due to increasing TJA demand[web:229]
**Pathogen Profile 2025:**[web:226]
• Gram-positive bacteria predominant
• High methicillin resistance rates
• Multidrug resistance increasing
• Culture-negative PJI common challenge
**🔬 ANTIBIOTIC THERAPY 2025:**[web:223][web:226]
**Empirical Treatment Strategies:**
1. **Early Postoperative PJI:**
• Broad-spectrum β-lactam + Gram-positive coverage
• Immediate surgical debridement
• Mixed infections common
2. **Culture-Negative Chronic PJI:**
• Preferred: Vancomycin + Meropenem
• Alternative: Linezolid + Meropenem
• High empirical success rates[web:226]
3. **Culture-Negative Acute Post-Op:**
• Suggested: Vancomycin + Ceftazidime
• Region-specific protocols important
**Targeted Therapy:**
• Rifampin for biofilm penetration
• Fluoroquinolones for skeletal distribution
• Daptomycin for high bioavailability
• Treatment individualized by pathogen/patient
**🔧 SURGICAL TREATMENT OPTIONS:**[web:223][web:231]
**1. DAIR (Debridement, Antibiotics, Implant Retention):**
• High success rates in infected UKA[web:226]
• Best for early acute PJI
• Requires biofilm-active antibiotics
• Timing critical for success
**2. Two-Stage Revision (GOLD STANDARD):**[web:231]
• Standard for serious chronic PJI
• Stage 1: Component removal + antibiotic spacer
• Mobile vs static spacer options
• Cement + soft tissue debridement
• Stage 2: Reimplantation after infection control
**3. One-Stage Revision:**
• Selected patients
• Known organism with antibiotic sensitivity
• Adequate soft tissue coverage
• Lower morbidity vs two-stage
**4. Salvage Procedures:**
• Chronic suppressive antibiotics (SAT)
• Resection arthroplasty
• Arthrodesis
• Amputation (last resort)
**🆕 NOVEL TECHNOLOGIES 2025:**[web:233][web:229]
**Cutting-Edge Therapeutics:**
• Peptide-based treatments
• Bacteriophage therapy
• Intraoperative anti-biofilm gel
• VT-X7 antibiotic pump
• Immune-based interventions
• Advanced biomarkers for detection
• Risk assessment tools
**Promise:**
• Revolutionizing PJI management
• Improved outcomes
• Reduced healthcare burden
**🎥 SURGICAL VIDEO DEMONSTRATIONS:**
1. Two-Stage Revision for PJI:
2. DAIR Procedure Technique:
3. Antibiotic Spacer Technique:
🖼️ **DIAGNOSTIC IMAGING & TOOLS:**
PJI Diagnostic Algorithms:
[Access diagnostic criteria and imaging protocols]
✅ **CLINICAL PEARLS 2025:**
**Diagnostic Criteria:**
• Identification of causative pathogens crucial
• Sensitive antibiotics essential for success
• Culture-negative PJI requires empirical approach
• Regional resistance patterns important
**Treatment Selection:**
1. Infection timing (acute vs chronic)
2. Pathogen identification
3. Antibiotic sensitivity
4. Host factors (comorbidities)
5. Bone stock quality
6. Soft tissue condition
**Success Factors:**
• Early diagnosis critical
• Aggressive surgical debridement
• Biofilm-active antibiotics
• Complete component/cement removal
• Adequate antibiotic duration
• Patient compliance essential
**Antibiotic Principles:**
• Biofilm penetration capability
• Optimal skeletal distribution
• High bioavailability
• IV therapy 2-4 weeks minimum
• Sequential oral therapy when appropriate
**DAIR Candidates:**
• Early post-op infection (<3-4 weeks)
• Acute hematogenous (<3 weeks symptoms)
• Well-fixed, functional components
• No sinus tract
• Organism with biofilm-active antibiotics
**Two-Stage Candidates:**
• Chronic PJI
• Failed DAIR
• Resistant organisms
• Compromised soft tissue
• Poor bone stock
• Loosened components
💡 **2025 PARADIGM SHIFTS:**
• Novel therapeutic modalities emerging
• Bacteriophage therapy showing promise
• Immune-based interventions developing
• Advanced diagnostic biomarkers
• Personalized treatment algorithms
• Focus on biofilm eradication
• Multi-disciplinary team approach essential
0
0 comments
Periprosthetic Joint Infection 2025: Novel Treatments & Diagnostic Advances with Videos
powered by
skool.com/orthopedic-surgeons-network-8446
A private global network for orthopedic surgeons to discuss complex cases, share experience, and stay ahead clinically.
Suggested communities
Powered by